Abstract
Background: To observe the changes of autophagy-related protein levels in peripheral blood lymphocytes before and after sirolimus treatment in children with systemic lupus erythematosus (SLE).Methods: Children with SLE were randomly divided into two groups, 28 in the traditional treatment group and 28 in the sirolimus group. Fifteen healthy children who were in the same period were collected as the normal control group. Clinical laboratory indexes, the percentage of routine lymphocytes, complement C3, complement C4, serum Anti-dsDNA and SLEDAI were detected.Results: At 3 and 6 months after treatment, compared with the traditional treatment group, the percentage of routine lymphocytes in the sirolimus group increased (P = 0.03), SLEDAI score and positive rate of Anti-dsDNA decreased (P = 0.01). Compared with normal children, the expression of microtubule-associated protein 1 light chain 3 (LC3) protein in peripheral blood lymphocytes was significantly higher (P = 0.006); peripheral blood expression of P62/SQSTM1 (sequestosome 1) protein in lymphocytes decreased (P = 0.02).Conclusion: Sirolimus can play a role in the treatment of systemic lupus erythematosus by regulating the level of autophagy.
Highlights
Systemic lupus erythematosus (SLE) is an autoimmune disease with disordered immune system regulation
Clinical Data The data is collected from children diagnosed with SLE (56 cases) who were admitted to the pediatric outpatient and inpatient of the Second Hospital of Hebei Medical University from December 2016 to June 2018, and the diagnosis was in accordance with the SLE classification standard [11] revised by the American College of Rheumatology (ACR) in 1997 or the SLE classification standard revised by the ACR/Systemic Lupus International Collaborating Clinic (SLICC) in 2009 [12]
1) Compared with the traditional treatment group, the percentage of blood routine lymphocytes increased at the end of 3 months of treatment in the sirolimus group, which was statistically significant (P = 0.03)
Summary
Systemic lupus erythematosus (SLE) is an autoimmune disease with disordered immune system regulation. SLE patients have autophagy in the peripheral blood mononuclear cells, and the expression of Beclin-1 and LC3 mRNA is significantly higher than normal [6, 7]. After comparing SLE patients with normal people, it was found that autophagy-related markers in B lymphocytes increased significantly. In the early stage of the onset of SLE, the LC3 expression level of lymphocytes was significantly increased, The Treatment With Lupus Erythematosus the autophagy of B lymphocytes was excessively activated, a large number of autophagosomes appeared, and there was a positive correlation change with the disease activity of SLE [8]. To observe the changes of autophagy-related protein levels in peripheral blood lymphocytes before and after sirolimus treatment in children with systemic lupus erythematosus (SLE)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
